ReviewCancer cell international2023
The role of LncRNAs in tumor immunotherapy.
Review in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Long non-coding RNAs and their potential role in predicting immunotherapy response and prognosis: a systematic review.Frontiers in immunology · 2026Pooled it
- LncRNA-LINC01281 exerts anti-cancer functions via the MYC/VEGF pathway in the progression of cervical cancer.Journal of cancer research and clinical oncology · 2026Article
- Regulatory roles of LncRNAs in colorectal cancer immune evasion: current concepts and future perspectives.Discover oncology · 2025Review
- Emerging Biomarkers to Predict Immunotherapy Response in Breast Cancer.Current oncology reports · 2025Review
- Identification of an immunomodulatory lncRNA signature associated with immune cell reprogramming in high-grade glioma.Cancer gene therapy · 2025Article
- The Interaction Between Vasculogenic Mimicry and the Immune System: Mechanistic Insights and Dual Exploration in Cancer Therapy.Cell proliferation · 2025Review
- Clinical significance of LINC01158 in breast cancer and inhibition of proliferation and metastasis of breast cancer cells by regulating miR-711.Hereditas · 2025Article
- Biological functions and affected signaling pathways by Long Non-Coding RNAs in the immune system.Non-coding RNA research · 2025Review
- Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma.Frontiers in immunology · 2025Review
- To Elucidate the Effective Role of Small Molecule Regulated lncRNAs in the Tumour Microenvironment in Immunotherapy.Current medicinal chemistry · 2025Review
- The Emerging Role of Long Non-coding RNA 01296 in Human Malignancies.Current molecular medicine · 2025Review
- Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy.Molecular and cellular biochemistry · 2024Review
- ARAP1-AS1: a novel long non-coding RNA with a vital regulatory role in human cancer development.Cancer cell international · 2024Review
- Hallmarks of cancer resistance.iScience · 2024Review
- Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors.Cancer cell international · 2024Review
- Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers.Clinical and experimental medicine · 2024Review
- Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.Frontiers in immunology · 2024Review
- B cells present a double-sided effect in digestive system tumors: a review for tumor microenvironment.Translational gastroenterology and hepatology · 2024Review
- An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer.Non-coding RNA · 2023Review
- PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer immunotherapy is a major breakthrough in the history of tumor therapy in the last decade. Immune checkpoint inhibitors blocking CTLA-4/B7 or PD-1/PD-L1 pathways have greatly prolonged the survival of patients with different cancers. Long non-coding RNAs (lncRNAs) are abnormally expressed in tumors and play an important role in tumor immunotherapy through immune regulation and immunotherapy resistance. In this review, we summarized the mechanisms of lncRNAs in regulating gene expression and well-studied immune checkpoint pathways. The crucial regulatory function of immune-related lncRNAs in cancer immunotherapy was also described. Further understanding of the underlying mechanisms of these lncRNAs is of great importance to the development of taking lncRNAs as novel biomarkers and therapeutic targets for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.